×
About 208 results

ALLMedicine™ Essential Thrombocytosis Center

Research & Reviews  77 results

Facial demodicosis in the immunosuppressed state: a retrospective case series from a te...
https://doi.org/10.1111/ijd.16162
International Journal of Dermatology; Amitay-Laish I, Solomon-Cohen E et. al.

Apr 11th, 2022 - Data on Demodex in the immunosuppressed state is limited, focusing mainly on patients with human immunodeficiency virus and hematological malignancies. The aim of this study was to describe the manifestations of facial demodicosis in diverse immun...

An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2V617F mye...
https://doi.org/10.1111/bjh.18165
British Journal of Haematology; Rabadan Moraes G, Pasquier F et. al.

Apr 1st, 2022 - Myeloproliferative neoplasms (MPN) are mainly sporadic but inherited variants have been associated with higher risk development. Here, we identified an EPOR variant (EPORP488S ) in a large family diagnosed with JAK2V617F -positive polycythaemia ve...

JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792018
Blood Cancer Journal; Pandey G, Kuykendall AT et. al.

Jan 28th, 2022 - The Philadelphia chromosome negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocytosis, and myelofibrosis, are driven by hyper activation of the JAK2 tyrosine kinase, the result of mutations in three MPN driving g...

Advances in polycythemia vera and lessons for acute leukemia.
https://doi.org/10.1016/j.beha.2021.101330
Best Practice & Research. Clinical Haematology; Spivak JL

Dec 7th, 2021 - The myeloproliferative neoplasms (MPN), polycythemia vera (PV), essential thrombocytosis and primary myelofibrosis, are an unusual group of myeloid neoplasms, which arise in a pluripotent hematopoietic stem cell (HSC) due to gain of function drive...

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT02098161

Nov 10th, 2021 - PRIMARY OBJECTIVES: I. To determine the efficacy of LCL161 as therapy for primary myelofibrosis (PMF), post-polycythemia vera (PV) myelofibrosis (MF) and post-essential thrombocytosis (ET) MF. II. To determine the objective response which is defin...

see more →

Clinicaltrials.gov  3 results

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT02098161

Nov 10th, 2021 - PRIMARY OBJECTIVES: I. To determine the efficacy of LCL161 as therapy for primary myelofibrosis (PMF), post-polycythemia vera (PV) myelofibrosis (MF) and post-essential thrombocytosis (ET) MF. II. To determine the objective response which is defin...

Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
https://clinicaltrials.gov/ct2/show/NCT03869476

Sep 12th, 2019 - The diagnostic criteria for myeloproliferative neoplasia have recently been revised in the WHO 2016 classification, which now recognizes a new entity between essential thrombocythemia (TE) and overt myelofibrosis (or primary myelofibrosis): prefib...

Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1-
https://clinicaltrials.gov/ct2/show/NCT02862366

Oct 31st, 2018 - Patients with myeloproliferative neoplasms Philadelphia chromosome negative (MPNsPh1-) such as Essential thrombocytosis (ET), Polycythemia vera (PV) and Primary Myelofibrosis (PMF) have a higher risk of arterial or deep-vein thrombosis. This is re...

see more →

News  3 results

5 Questions... with Charles Morris, MD, VP of Worldwide Clinical Research, for Cephalon Oncology
https://www.onclive.com/view/ong_5qs_with_charles_morris

Mar 15th, 2022 - 1 Why are self-survival and self-renewing pathways such promising areas of discovery at this time for Cephalon? If we can understand the methods and the pathways by which cells are able to either prolong their survival or sustain their own prolif...

Case Report: Headache in a Postpartum Patient With Essential Thrombocytosis
https://www.mdedge.com/emergencymedicine/article/82551/hematology/case-report-headache-postpartum-patient-essential
Caleb P. Canders, MD, Taku Taira, MD

May 1st, 2014 - Case A 32-year-old woman, 4 weeks postpartum, presented to the ED with a chief complaint of headache, which she stated had become worse over the past 4 days. The headache was gradual-onset, bioccipital, and pressure-like.

C. albicans appendicitis in a neutropenic patient after induction chemotherapy
https://www.mdedge.com/hematology-oncology/article/77462/leukemia-myelodysplasia-transplantation/c-albicans-appendicitis
Rohtesh S. Mehta, MD, MPH, MS, David Cohen, MD

Sep 4th, 2013 - A 62-year-old white man with a past medical history of hypertension and essential thrombocytosis diagnosed 17 years ago presented at our institution. He was being treated with hydroxyurea, with which he required occasional blood transfusions and p.

see more →